Ahmad Arham, MD
Interventional Cardiology · Iowa City, IANPI 1336390392
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $2,169 of the $2,842 with a category attached, or 76.3%. 16 manufacturers reported payments, led by Abbott at 37.5% of the total. Reporting peaked in 2020 at $1,096 and has fallen 98.7% since, to $15 in 2025. That places this record below the midpoint for interventional cardiology clinicians in IA, where the typical reported total is $3,872.
Across 76 payments — averaging $37.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$1K
- Johnson & Johnson$315
- Novartis$300
- Medtronic$294
- Boston Scientific$247
- AstraZeneca$183
- plus $438 from 10 others
What the payments were for
- Travel & lodging$67324%
- Food & beverage$2,16976%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 6 | $1,064 |
| Johnson & Johnson | 11 | $315 |
| Novartis | 19 | $300 |
| Medtronic(2 entities) | 4 | $294 |
| Boston Scientific | 3 | $247 |
| AstraZeneca | 12 | $183 |
| Philips North America LLC | 1 | $118 |
| Boehringer Ingelheim | 6 | $87 |
| Gilead | 3 | $52 |
| E.r. Squibb & Sons, L.L.C. | 3 | $46 |
| Amgen | 2 | $36 |
| Livanova USA, Inc. | 1 | $27 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 2 | $22 |
| Teleflex LLC | 1 | $21 |
| Terumo Medical Corporation | 1 | $15 |
| Amarin Pharma, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,842 in reported general payments places this provider in the 40th percentile of 64 interventional cardiology providers in Iowa.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 114 | $142,027 |
| EntrestoSacubitril/Valsartan | 50 | $56,461 |
| XareltoRivaroxaban | 24 | $33,664 |
| JardianceEmpagliflozin | 16 | $17,246 |
| Repatha SureclickEvolocumab | 19 | $14,749 |
| BrilintaTicagrelor | 18 | $12,491 |
| Varenicline Tartrate | 14 | $3,295 |
| Metoprolol Succinate | 166 | $1,975 |
| Bumetanide | 43 | $1,924 |
| Amiodarone Hcl | 71 | $1,865 |
| Ezetimibe | 51 | $1,656 |
| Atorvastatin Calcium | 128 | $1,388 |
| Rosuvastatin Calcium | 72 | $974 |
| Diltiazem 24hr Er (Cd)Diltiazem Hcl | 35 | $901 |
| Isosorbide Dinitrate | 14 | $899 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| NovartisEntresto | $300 | $56,46150 claims |
| Johnson & JohnsonXarelto | $315 | $33,66424 claims |
| Boehringer IngelheimJardiance | $87 | $17,24616 claims |
| AstraZenecaBrilinta | $183 | $12,49118 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 64 interventional cardiology providers in Iowa.
Other interventional cardiology in Iowa City
- Jason AllenIowa City$30K
- Hossein OuranosIowa City$28K
- Spas KotevIowa City$12K
- Waqas SiddiquiIowa City$10K
- Hisham IbrahimIowa City$8K
- Yehia SalehIowa City$6K
- James RossenIowa City$5K
- Connor YoungIowa City$4K
- Vikram SharmaIowa City$3K
- Phillip HorwitzIowa City$3K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.